$CCEL
CRYO CELL INTERNATIONAL INC

2014 Form 10-K Financial Statement

#000119312515073665 Filed on March 02, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013
Revenue $20.13M $4.710M $18.99M
YoY Change 5.96% -2.28% 5.7%
Cost Of Revenue $5.632M $1.310M $5.322M
YoY Change 5.82% -1.5% 8.88%
Gross Profit $14.49M $3.400M $13.67M
YoY Change 6.01% -2.86% 4.52%
Gross Profit Margin 72.02% 72.19% 71.98%
Selling, General & Admin $12.25M $2.880M $11.37M
YoY Change 7.79% -26.53% -21.21%
% of Gross Profit 84.53% 84.71% 83.13%
Research & Development $64.37K $10.00K $36.17K
YoY Change 77.97% -50.0% -67.01%
% of Gross Profit 0.44% 0.29% 0.26%
Depreciation & Amortization $375.0K $90.00K $379.0K
YoY Change -1.06% -43.75% -3.56%
% of Gross Profit 2.59% 2.65% 2.77%
Operating Expenses $12.32M $2.930M $11.40M
YoY Change 8.01% -26.57% -21.56%
Operating Profit $1.981M $470.0K $1.703M
YoY Change 16.35% -195.92% -199.51%
Interest Expense $1.151M -$610.0K $1.401M
YoY Change -17.79% 117.86% 36.98%
% of Operating Profit 58.12% -129.79% 82.25%
Other Income/Expense, Net -$941.2K $20.00K -$1.352M
YoY Change -30.37% 100.0% -47.09%
Pretax Income $677.1K -$130.0K $197.0K
YoY Change 243.7% -83.95% -104.46%
Income Tax $123.5K $40.00K $169.6K
% Of Pretax Income 18.24% 86.07%
Net Earnings $553.6K -$170.0K $27.44K
YoY Change 1917.87% -80.0% -100.43%
Net Earnings / Revenue 2.75% -3.61% 0.14%
Basic Earnings Per Share $0.05 $0.00
Diluted Earnings Per Share $0.05 -$15.50K $0.00
COMMON SHARES
Basic Shares Outstanding 10.18M shares 10.76M shares 10.86M shares
Diluted Shares Outstanding 10.43M shares 10.97M shares

Balance Sheet

Concept 2014 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.382M $3.960M $3.930M
YoY Change -13.95% 47.76% 46.64%
Cash & Equivalents $3.279M $3.925M $3.930M
Short-Term Investments $102.7K $40.00K
Other Short-Term Assets $1.038M $155.0K $1.610M
YoY Change -35.53% -95.22% -50.31%
Inventory $0.00
Prepaid Expenses $490.0K
Receivables $4.072M $3.336M $3.340M
Other Receivables $0.00 $550.0K $550.0K
Total Short-Term Assets $8.492M $9.463M $9.430M
YoY Change -9.95% 1.59% 1.18%
LONG-TERM ASSETS
Property, Plant & Equipment $953.4K $1.207M $1.210M
YoY Change -21.2% -5.76% -5.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $684.0K $720.0K
YoY Change -100.0% -2.29% 2.86%
Other Assets $51.85K $830.1K $90.00K
YoY Change -42.39% -52.14% 12.5%
Total Long-Term Assets $1.718M $2.037M $2.070M
YoY Change -17.02% -32.44% -31.23%
TOTAL ASSETS
Total Short-Term Assets $8.492M $9.463M $9.430M
Total Long-Term Assets $1.718M $2.037M $2.070M
Total Assets $10.21M $11.50M $11.50M
YoY Change -11.22% -6.73% -6.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $992.9K $1.195M $1.190M
YoY Change -16.56% -1.25% -1.65%
Accrued Expenses $1.472M $1.801M $1.800M
YoY Change -18.24% -38.28% -38.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $9.127M $9.810M $9.810M
YoY Change -6.96% -8.0% -7.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.300M $0.00
YoY Change 0.0%
Other Long-Term Liabilities $11.81M $10.96M $10.96M
YoY Change 7.75% 2.76% 2.81%
Total Long-Term Liabilities $11.81M $13.26M $10.96M
YoY Change 7.75% 2.27% 2.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.127M $9.810M $9.810M
Total Long-Term Liabilities $11.81M $13.26M $10.96M
Total Liabilities $20.94M $23.07M $20.77M
YoY Change 0.8% -2.37% -2.63%
SHAREHOLDERS EQUITY
Retained Earnings -$33.73M
YoY Change -0.08%
Common Stock $27.38M
YoY Change 22989.41%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.926M
YoY Change 33.77%
Treasury Stock Shares
Shareholders Equity -$10.73M -$9.268M -$9.270M
YoY Change
Total Liabilities & Shareholders Equity $10.21M $11.50M $11.50M
YoY Change -11.22% -6.73% -6.73%

Cashflow Statement

Concept 2014 2013 Q4 2013
OPERATING ACTIVITIES
Net Income $553.6K -$170.0K $27.44K
YoY Change 1917.87% -80.0% -100.43%
Depreciation, Depletion And Amortization $375.0K $90.00K $379.0K
YoY Change -1.06% -43.75% -3.56%
Cash From Operating Activities $1.555M -$20.00K $822.0K
YoY Change 89.16% -106.25% 127.76%
INVESTING ACTIVITIES
Capital Expenditures $120.5K -$130.0K $349.8K
YoY Change -65.55% 161.94%
Acquisitions
YoY Change
Other Investing Activities $511.7K $410.0K $1.550M
YoY Change -66.99% 485.71% 38.39%
Cash From Investing Activities $391.2K $290.0K $1.149M
YoY Change -65.97% 314.29% 19.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.671M $738.6K
YoY Change 261.63% -56.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.592M -60.00K -723.7K
YoY Change 258.16% -86.05% -85.38%
NET CHANGE
Cash From Operating Activities 1.555M -20.00K 822.0K
Cash From Investing Activities 391.2K 290.0K 1.149M
Cash From Financing Activities -2.592M -60.00K -723.7K
Net Change In Cash -645.9K 210.0K 1.248M
YoY Change -151.76% -625.0% -134.4%
FREE CASH FLOW
Cash From Operating Activities $1.555M -$20.00K $822.0K
Capital Expenditures $120.5K -$130.0K $349.8K
Free Cash Flow $1.434M $110.0K $472.2K
YoY Change 203.75% -65.63% 107.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q2 dei Entity Public Float
EntityPublicFloat
18091915
CY2011Q3 ccel Restricted Cash Transferred To Trust
RestrictedCashTransferredToTrust
2500000
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000 shares
CY2013Q2 ccel Operating Lease Property Leased Area Covered Under Amended Agreement
OperatingLeasePropertyLeasedAreaCoveredUnderAmendedAgreement
9600 sqft
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10001723 shares
CY2011Q2 ccel Number Of Directors Nominated
NumberOfDirectorsNominated
5 Directors
CY2012Q2 ccel Number Of Directors Nominated
NumberOfDirectorsNominated
6 Directors
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000 shares
CY2009Q4 ccel Payment For Sponsor Fees
PaymentForSponsorFees
100000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-8997765
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1367465
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2677382
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11870040 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10743225 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.79
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2013Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
1276915 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
109152 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10852000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8658354
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5567799
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9810433
CY2013Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
365392
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
914114
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
118700
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1194825
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33725902
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
27265340
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1800811
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-9267985
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
10958354
CY2013Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2300000
CY2013Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11500802
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7123
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
58764
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6814797
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
551585
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1994575
CY2013Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
462541
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3925156
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1207279
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
968130
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10852000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
45000
CY2013Q4 us-gaap Equity Method Investments
EquityMethodInvestments
684000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
56634
CY2013Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
550782
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3790000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
392000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1099000
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37910
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6775078
CY2013Q4 us-gaap Assets
Assets
11500802
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3336460
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
154984
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
830116
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2926123
CY2013Q4 us-gaap Assets Current
AssetsCurrent
9463407
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
0
CY2013Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
63757
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
489985
CY2013Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
146116
CY2013Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
3055000
CY2013Q4 ccel Investment Held In Trust
InvestmentHeldInTrust
764192
CY2013Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
96000
CY2013Q4 ccel Accrued Legal Settlement
AccruedLegalSettlement
525000
CY2013Q4 ccel Unamortized Sponsor Fees
UnamortizedSponsorFees
27000
CY2013Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
16000
CY2013Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1090000
CY2014Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
612043
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3279267
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2300000
CY2014Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2013Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1285000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11921285 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9706174 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
1.64
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
2.14
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2014Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
2.14
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
970183 shares
CY2014Q4 us-gaap Treasury Stock Number Of Shares Held
TreasuryStockNumberOfSharesHeld
2215111 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
27083 shares
CY2014Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
997266 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10517000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
9509088
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5919277
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9127161
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
430020
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
403975
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
119213
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
992910
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33575334
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
27842106
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1471699
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-10726663
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11809088
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
17640
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10209586
CY2014Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6212
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25661
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6662552
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
211170
CY2014Q4 us-gaap Deferred Revenue
DeferredRevenue
0
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1976966
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1863
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
953415
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
204141
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10517000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
49000
CY2014Q4 us-gaap Equity Method Investments
EquityMethodInvestments
684000
CY2014Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28358
CY2014Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
0
CY2014Q4 us-gaap Cash Collateral For Borrowed Securities
CashCollateralForBorrowedSecurities
200000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
4151000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
391000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1066000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1863
CY2014Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
102674
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6872692
CY2014Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
200000
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
19043
CY2014Q4 us-gaap Assets
Assets
10209586
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1863
CY2014Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2133000
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4071997
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1863
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
123126
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
764212
CY2014Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5112648
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8491959
CY2014Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1863
CY2014Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34570
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
710754
CY2014Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
80212
CY2014Q4 ccel Deferred Tax Asset Net Operating Loss Credits And Other Carry Forward
DeferredTaxAssetNetOperatingLossCreditsAndOtherCarryForward
2260000
CY2014Q4 ccel Investment Held In Trust
InvestmentHeldInTrust
0
CY2014Q4 ccel Deferred Tax Assets Tax Deferred Expense Depreciation And Amortization
DeferredTaxAssetsTaxDeferredExpenseDepreciationAndAmortization
165000
CY2014Q4 ccel Number Of Employee Stock Based Compensation Plan
NumberOfEmployeeStockBasedCompensationPlan
3 CompensationPlan
CY2014Q4 ccel Unamortized Sponsor Fees
UnamortizedSponsorFees
7000
CY2014Q4 ccel Reserves Recorded Under Programs
ReservesRecordedUnderPrograms
17000
CY2014Q4 ccel Deferred Tax Assets Tax Revenue Sharing Agreements Buy Out
DeferredTaxAssetsTaxRevenueSharingAgreementsBuyOut
1018000
CY2014Q4 ccel Deferred Tax Asset From Unconsolidated Affiliate
DeferredTaxAssetFromUnconsolidatedAffiliate
1417000
CY2013Q4 ccel Minimum Jurisdictional Amount
MinimumJurisdictionalAmount
75000
CY2006Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11032
CY2006Q2 ccel Date Of Additional Operating Lease
DateOfAdditionalOperatingLease
2006-08-01
CY2006Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2006Q2 ccel Termination Period Of Operating Lease
TerminationPeriodOfOperatingLease
2013
CY2006Q2 ccel Maximum Amount Of Lease Rental Expense For Additional Space Under Lease Term
MaximumAmountOfLeaseRentalExpenseForAdditionalSpaceUnderLeaseTerm
13176
CY2012Q1 ccel Additional Payment Warranty
AdditionalPaymentWarranty
10000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2013Q2 ccel Lease Agreement Termination Fee
LeaseAgreementTerminationFee
150000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36168
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2013Q2 ccel Extended Operating Lease Area Of Facility
ExtendedOperatingLeaseAreaOfFacility
17600 sqft
CY2004Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
141000
CY2004Q2 ccel Operating Lease Area Of Facility
OperatingLeaseAreaOfFacility
17600 sqft
CY2004Q2 ccel Operating Lease Period
OperatingLeasePeriod
P10Y
CY2013Q4 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
525000
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.858 pure
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
107932 shares
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
821980
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.863 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.584 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10972484 shares
CY2013 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
738618
CY2013 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-564723
CY2013 us-gaap Revenues
Revenues
18994614
CY2013 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
37693
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
349784
CY2013 us-gaap Net Income Loss
NetIncomeLoss
27436
CY2013 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
78266
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
1444000
CY2013 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
47525
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10864552 shares
CY2013 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-1608714
CY2013 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
12800
CY2013 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
24250
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2013 us-gaap Licenses Revenue
LicensesRevenue
1296979
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
197016
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-44428
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14950
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
1702788
CY2013 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
170000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
426012
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1351721
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
351067
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1316135
CY2013 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
17697635
CY2013 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
48851
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
39071
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-53281
CY2013 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-154051
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
272000
CY2013 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
206000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
572458
CY2013 us-gaap Interest Expense
InterestExpense
1400572
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-15148
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
271961
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-723668
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1116947
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1149462
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14950
CY2013 us-gaap Advertising Expense
AdvertisingExpense
615000
CY2013 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
169000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
169000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
17291826
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
7000
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
419864
CY2013 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11366417
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
816464
CY2013 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
738618
CY2013 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
267620
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
394000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1247774
CY2013 us-gaap Cost Of Services
CostOfServices
5322271
CY2013 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2013 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
378837
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
67000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
169580
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2013 us-gaap Depreciation
Depreciation
379000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
188133
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-115000
CY2013 us-gaap Sponsor Fees
SponsorFees
20000
CY2013 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2013 ccel Effective Income Tax Rate Reconciliation Capital Loss Expirations
EffectiveIncomeTaxRateReconciliationCapitalLossExpirations
0.00 pure
CY2013 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
210000
CY2013 ccel Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2013 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
1047850
CY2013 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-31140
CY2013 ccel Number Of Installments Received
NumberOfInstallmentsReceived
12 Installment
CY2013 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1296979
CY2013 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
170000
CY2013 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
1.066 pure
CY2013 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
112000
CY2013 ccel Revenue Associated With Agreements
RevenueAssociatedWithAgreements
50000
CY2013 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.863 pure
CY2013 ccel Legal Fee Paid On Behalf Of Participants
LegalFeePaidOnBehalfOfParticipants
97140
CY2013 ccel Depreciation And Amortization Expense
DepreciationAndAmortizationExpense
394502
CY2014 dei Document Type
DocumentType
10-K
CY2014 us-gaap Concentration Risk Supplier
ConcentrationRiskSupplier
Company depends on one supplier for the source of its collection kits
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
29160 shares
CY2014 dei Trading Symbol
TradingSymbol
CCEL
CY2014 dei Entity Registrant Name
EntityRegistrantName
CRYO CELL INTERNATIONAL INC
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.60
CY2014 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
2215111 shares
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.15 pure
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.151 pure
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
253229 shares
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
1554821
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
One Common Share per Right
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
75409 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
2017-12-05
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.036 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.155 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
22500 shares
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-11-30
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.377 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
1.78
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
1.81
CY2014 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
2.31
CY2014 us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
Open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10429035 shares
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2014 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P20Y
CY2014 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Product Warranty and Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> Program</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $50,000 to its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February&#xA0;1, 2012, the Company increased the $50,000 payment warranty to a $75,000 payment warranty to all of its new clients. Additionally, under the Cryo-Cell Cares<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">TM</sup> program, the Company will pay $10,000 to the client to offset personal expenses if the umbilical cord blood product is used for bone marrow reconstitution in a myeloblative transplant procedure. The product warranty and the Cryo-Cell Cares program are available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties. The Company does not maintain insurance for this warranty program and therefore maintains reserves to cover any estimated potential liabilities. The Company&#x2019;s reserve balance is based on the $75,000 or $50,000 (as applicable) maximum payment and the $10,000 maximum expense reimbursement multiplied by formulas to determine the projected number of units requiring a payout. The Company determined the estimated expected usage and engraftment failure rates based on an analysis of the historical usage and failure rates and the historical usage and failure rates in other private and public cord blood banks based on published data. The Company&#x2019;s estimates of expected usage and engraftment failure could change as a result of changes in actual usage rates or failure rates and such changes would require an adjustment to the established reserves. The historical usage and failure rates have been very low and a small increase in the number of transplants or engraftment failures could cause a significant increase in the estimated rates used in determining the Company&#x2019;s reserve. In addition, the reserve will increase as additional umbilical cord blood specimens are stored which are subject to the warranty. As of November&#xA0;30, 2014 and November&#xA0;30, 2013 the Company recorded reserves under these programs in the amounts of approximately $17,000 and $16,000, respectively, which are included in accrued expenses in the accompanying consolidated balance sheets.</p> </div>
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P20D
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0000862692
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Risks</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash and cash equivalent accounts in financial institutions, which often exceed the Federal Depository Insurance (FDIC) limit. The Company places its cash with high quality financial institutions and believes it is not exposed to any significant credit risk. The Company may from time to time invest some of its cash funds in certificates of deposit and bond investments maintained by brokers who are insured under the Securities Investor Protection Corporation (SIPC). The Company believes these are conservative investments with a low risk for any loss of principal. The Company regularly assesses its marketable security investments for impairment and adjusts its investment strategy as it deems appropriate.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> The Company depends on one supplier for the source of its collection kits, a critical component of the umbilical cord blood stem cell collection process. However, the Company believes that alternative sources of supply are available.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 8%"> As of November&#xA0;30, 2013, the Company has amounts due from certain foreign license affiliates that account for approximately 42% of accounts receivable on the consolidated balance sheets. During 2014, there were no single licensees with amounts due that exceeded 10% individually.</p> </div>
CY2014 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2015-12-31
CY2014 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2014 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassification</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> During 2014, the Company reclassified the 2013 prepaid expenses from other current assets. This reclassification did not have an impact on total assets, liabilities, stockholders&#x2019; deficit, net income (loss) or net income (loss) per common share.</p> </div>
CY2014 us-gaap Revenue Recognition Services Royalty Fees
RevenueRecognitionServicesRoyaltyFees
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>License and Royalty Agreements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"> The Company has entered into licensing agreements with certain investors in various international markets in an attempt to capitalize on the Company&#x2019;s technology. The investors typically pay a licensing fee to receive Company marketing programs, technology and know-how in a selected area. The investor may be given a right to sell sub-license agreements as well. As part of the accounting for the up-front license fee paid, or payable, to the Company, revenue from the up-front license fee is recognized based on such factors as when the payment is due, collectability and when all material services or conditions relating to the sale have been substantially performed by the Company based on the terms of the agreement. The Company has twelve active licensing agreements. The following areas each have one license agreement: El Salvador, Guatemala, Panama, Honduras, China and Pakistan. The following areas each have two license agreements: India, Nicaragua and Costa Rica.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"> In addition to the license fee, the Company earns processing and storage fees on subsequent processing and storage revenues received by the licensee in the licensed territory and a fee on any sub-license agreements that are sold by the licensee where applicable. These fees are included in processing and storage fees revenue on the consolidated statements of operations. As part of the accounting for royalty revenue from India, the Company uses estimates and judgments based on historical processing and storage volume in determining the timing and amount of royalty revenue to recognize. The Company periodically reviews license and royalty receivables for collectability and, if necessary, will record an expense for an allowance for uncollectible accounts.</p> </div>
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10175806 shares
CY2014 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-763989
CY2014 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
-31700
CY2014 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
64764
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2014 us-gaap Licenses Revenue
LicensesRevenue
1471486
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
677149
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79142
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1981234
CY2014 us-gaap Income Tax Reconciliation Tax Credits Foreign
IncomeTaxReconciliationTaxCreditsForeign
124000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
498137
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-941201
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1040033
CY2014 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
346754
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
1874000
CY2014 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2671060
CY2014 us-gaap Increase Decrease In Notes Receivables
IncreaseDecreaseInNotesReceivables
-550782
CY2014 us-gaap Revenues
Revenues
20126546
CY2014 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
187500
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
120517
CY2014 us-gaap Net Income Loss
NetIncomeLoss
553623
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2038973
CY2014 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
18655060
CY2014 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
210258
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
220769
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-31858
CY2014 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-362884
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
404000
CY2014 us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
206000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
0
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
698489
CY2014 us-gaap Interest Expense
InterestExpense
1151459
CY2014 us-gaap Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
81480
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64367
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12251921
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1303436
CY2014 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
2671060
CY2014 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
1667799
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-645889
CY2014 us-gaap Cost Of Services
CostOfServices
5632041
CY2014 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2014 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
25649
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
272000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123526
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Depreciation
Depreciation
375000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
171334
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-2591918
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-329112
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
391208
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
79142
CY2014 us-gaap Advertising Expense
AdvertisingExpense
621000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-123000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-123000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
18145312
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
29000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
256546
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-201915
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
404233
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-301000
CY2014 us-gaap Sponsor Fees
SponsorFees
20000
CY2014 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2014 ccel Exhibit Display Period
ExhibitDisplayPeriod
P5Y
CY2014 ccel Common Stock Repurchase Average Price Per Share
CommonStockRepurchaseAveragePricePerShare
2.35
CY2014 ccel Number Of Deliverables For Revenue Recognized
NumberOfDeliverablesForRevenueRecognized
2 Deliverables
CY2014 ccel Effective Income Tax Rate Reconciliation Capital Loss Expirations
EffectiveIncomeTaxRateReconciliationCapitalLossExpirations
0.00 pure
CY2014 ccel Net Cash Proceeds From Sale Of Assets Percentage
NetCashProceedsFromSaleOfAssetsPercentage
0.50 pure
CY2014 ccel Minimum Percentage Probability Of Realized Tax Benefit On Settlement
MinimumPercentageProbabilityOfRealizedTaxBenefitOnSettlement
0.50 pure
CY2014 ccel Income Tax Reconciliation Permanent Disallowances
IncomeTaxReconciliationPermanentDisallowances
123000
CY2014 ccel Deferred Revenue Recognition Period
DeferredRevenueRecognitionPeriod
P12M
CY2014 ccel Income Tax Reconciliation Capital Loss Expirations
IncomeTaxReconciliationCapitalLossExpirations
0
CY2014 ccel Payment To Participants Of Profit Sharing Agreement
PaymentToParticipantsOfProfitSharingAgreement
1926980
CY2014 ccel Common Stock Additional Share Repurchased
CommonStockAdditionalShareRepurchased
8506 shares
CY2014 ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
-37628
CY2014 ccel Date Of Amendment Related To License Agreement
DateOfAmendmentRelatedToLicenseAgreement
2011-10-17
CY2014 ccel Process And Storage Royalties
ProcessAndStorageRoyalties
1471486
CY2014 ccel Income Tax Reconciliation Foreign Tax Withholding
IncomeTaxReconciliationForeignTaxWithholding
124000
CY2014 ccel Effective Income Tax Rate Reconciliation Permanent Disallowances
EffectiveIncomeTaxRateReconciliationPermanentDisallowances
0.152 pure
CY2014 ccel Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
107000
CY2014 ccel Number Of License Agreement
NumberOfLicenseAgreement
2 Agreement
CY2014 ccel Associate Stock Purchase Plan Price Percentage Of Common Stock Market Price
AssociateStockPurchasePlanPricePercentageOfCommonStockMarketPrice
0.50 pure
CY2014 ccel Types Of License Agreements
TypesOfLicenseAgreements
2 Agreement
CY2014 ccel Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm
P5Y10M2D
CY2014 ccel Operating Loss Carryforwards Expiration Date Description
OperatingLossCarryforwardsExpirationDateDescription
Expire during 2024 through 2033
CY2014 ccel Period For Doubtful Of Accounts Receivable Due From Client
PeriodForDoubtfulOfAccountsReceivableDueFromClient
P30D
CY2014 ccel Effective Income Tax Rate Foreign Tax Withholding
EffectiveIncomeTaxRateForeignTaxWithholding
0.155 pure
CY2014 ccel Legal Fee Paid On Behalf Of Participants
LegalFeePaidOnBehalfOfParticipants
0
CY2014 ccel Number Of Licensing Agreement Made By Entity
NumberOfLicensingAgreementMadeByEntity
12 Agreement
CY2014 ccel Depreciation And Amortization Expense
DepreciationAndAmortizationExpense
377008
CY2014 ccel Date Of Notification Received Related To Terminating License Agreement
DateOfNotificationReceivedRelatedToTerminatingLicenseAgreement
2011-08-19
CY2014 ccel Treasury Stock From Affiliates
TreasuryStockFromAffiliates
81480

Files In Submission

Name View Source Status
0001193125-15-073665-index-headers.html Edgar Link pending
0001193125-15-073665-index.html Edgar Link pending
0001193125-15-073665.txt Edgar Link pending
0001193125-15-073665-xbrl.zip Edgar Link pending
ccel-20141130.xml Edgar Link completed
ccel-20141130.xsd Edgar Link pending
ccel-20141130_cal.xml Edgar Link unprocessable
ccel-20141130_def.xml Edgar Link unprocessable
ccel-20141130_lab.xml Edgar Link unprocessable
ccel-20141130_pre.xml Edgar Link unprocessable
d832967d10k.htm Edgar Link pending
d832967dex23.htm Edgar Link pending
d832967dex311.htm Edgar Link pending
d832967dex312.htm Edgar Link pending
d832967dex313.htm Edgar Link pending
d832967dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending